In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.
Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?
Given similar efficacy and the renal and bone benefits, TAF/FTC should be favored over TDF/FTC. But as David Wohl, M.D., explains, the reality isn't so simple.
A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.
The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?
This is clearly an antiretroviral not built for daily administration. But then what is it destined for?
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
An international team of experts conducted a thoughtful review of existing research regarding the use of doxycycline for STI prevention. Do the risks of its use outweigh the benefits?
Sobering data make clear that in HIV clinics, depression screening is as important as STI screening.
The attention of this specific U.S. president on HIV is curious. However, while it may be initially disorienting, it makes sense, explains David Wohl, M.D.